Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ
547.71
-0.34 (-0.06%)
Closed
Aug 24, 2026
Day's Range
542.89550.51
52 wk Range
374.17555.32
Financial Statements - VRTX - Vertex Pharmaceuticals Incorporated
Revenue
12.00B▲ 8.9%
Net Income
3.95B▲ 838.1%Net Margin 32.9%
EBITDA
5.24B▲ 980.2%
Free Cash Flow
3.19B▲ 426.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 12B | 11.02B | 9.86B | 8.93B | 7.57B | 6.20B |
| Cost of Goods | 1.65B | 1.53B | 1.26B | 1.08B | 904.20M | 736.30M |
| Gross Profit | 10.35B | 9.48B | 8.60B | 7.85B | 6.67B | 5.46B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 4.55B | -233.40M | 4.30B | 4.36B | 3.89B | 2.86B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -388.80M | -85.60M | -498.30M | -222.80M | -1.10B | 283.50M |
| Pre Tax Income | 4.64B | 248.50M | 4.37B | 4.23B | 2.73B | 3.11B |
| Income Tax | 690M | 784.10M | 760.20M | 910.40M | 388.30M | 405.20M |
| Net Income | 3.95B | -535.60M | 3.61B | 3.32B | 2.34B | 2.71B |
| EPS Basic | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 |
| EPS Diluted | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 |
| Basic Shares Outstanding | 255.70M | 257.90M | 257.70M | 256.10M | 257.70M | 259.84M |
| Diluted Shares Outstanding | 255.70M | 257.90M | 257.70M | 256.10M | 257.70M | 259.84M |
| Ebit | 4.65B | 279.10M | 4.42B | 4.28B | 2.79B | 3.17B |
| Ebitda | 5.24B | 485.80M | 5.08B | 4.49B | 4.02B | 3.29B |
| Net Income Continuous Operations | 3.95B | -535.60M | 3.61B | 3.32B | 2.34B | 2.71B |
| Minority Interests | - | - | - | - | - | 0 |
| Preferred Stock Dividends | - | - | - | - | - | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
